Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 4, 1997, Pages 525-535

  Jones, Robert L ^a   Qian, Yue Ming ^a   Wise, Helen ^a   Wong, Henry N C ^a   Lam, Wai Lun ^a   Chan, Ho Wai ^a   Yim, Anthony P C ^a   Ho, Jonathan K S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cicaprost; Human pulmonary artery; IP receptors; Nonprostanoid prostacyclin mimetics; Pulmonary vasodilators; TP receptor antagonists

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; [3 [4 (4,5 DIPHENYL 2 OXAZOLYL) 5 OXAZOLYL]PHENOXY]ACETIC ACID; BMY 42393; CICAPROST; CU 23; CU 602; ILOPROST; OCTIMIBATE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; TAPROSTENE; TEI 3356; TEI 9063; UNCLASSIFIED DRUG; VAPIPROST;

ADULT; AGED; ARTERY ENDOTHELIUM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECEPTOR OCCUPANCY; VASODILATATION;

ACETATES; AGED; CARDIOVASCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPOPROSTENOL; FATTY ACIDS; HUMANS; ILOPROST; IMIDAZOLES; INDOLES; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; OXAZOLES; PHENOXYACETATES; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDINS, SYNTHETIC; PULMONARY ARTERY; RECEPTORS, EPOPROSTENOL; RECEPTORS, PROSTAGLANDIN; STRUCTURE-ACTIVITY RELATIONSHIP; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 0030970338     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199704000-00015     Document Type: Article

References (43)

1. Cremona G, Higenbottam T. Role of prostacyclin in the treatment of pulmonary hypertension. Am J Cardiol 1995;75:67-71A.
2. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
3. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W. Aerolised prostacyclin in adult respiratory distress syndrome. Lancet 1993;342:961-2.
4. Goldman AP, Delius RE, Deanfield JE, Macrae DJ. Nitric oxide is superior to prostacyclin for pulmonary hypertension after cardiac operations. Ann Thorac Surg 1995;60:300-6.
5. Coleman RA, Smith WL, Narumiya S. VIII International Union of Pharmacology Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994;46:205-28.
6. Dong YJ, Jones RL, Wilson NH. Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues. Br J Pharmacol 1986;87:97-107.
7. Lawrence RA, Jones RL, Wilson NH. Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea pig ileum. Br J Pharmacol 1992;105:271-8.
8. Dong YJ, Jones RL. Effects of prostaglandin and thromboxane analogues on bullock and dog iris sphincter preparations. Br J Pharmacol 1982;76:149-55.
9. Coleman RA, Humphray JM, Sheldrick RLG, White BP. Gastric antisecretory prostanoids: actions at different prostanoid receptors. Br J Pharmacol 1988;95:724P.
10. 3 receptor. Prostaglandins 1993;48:275-83.
11. 3-receptor agonists on human isolated pulmonary artery. Br J Pharmacol 1994;113:369-74.
12. Michel G, Seipp U. In vitro studies with the stabilized epoprostenol analog taprostene. Arzneimittelforschung 1990;40:817-22.
13. Flohe L, Bohlke H, Frankus E, et al. Designing prostacyclin analogues. Arzneimittelforschung 1983;33:1240-8.
14. Mori S, Takechi S. Synthesis of benzodioxane prostacyclin analogue. Heterocycles 1990;31:1189-93.
15. Armstrong RA, Jones RL, MacDermot J, Wilson NH. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics. Br J Pharmacol 1986;87:543-51.
16. Seiler SM, Brassard CL, Arnold AJ, Meanwell NA, Fleming JS, Keely SL Jr. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation. J Pharmacol Exp Ther 1990;255:1021-6.
17. Jones RL, Wilson NH, Marr CG, Muir G, Armstrong RA. Diphenylmethylazine prostanoids with prostacyclin-like actions on human platelets. J Lipid Res 1993;6:405-10.
18. Meanwell NA, Romine JL, Seiler SM. Non-prostanoid prostacyclin mimetics. Drugs Future 1994;19:361-85.
19. Meanwell NA, Romine JL, Rosenfeld MJ, et al. Non-prostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid. J Med Chem 1993;36:3884-903.
20. Merritt JE, Hallam TJ, Brown AM, et al. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation acts via the prostacyclin receptor. Br J Pharmacol 1991;102:251-9.
21. Merritt JE, Brown AM, Bund S, et al. Primate vascular responses to octimibate, a non-prostanoid agonist at the prostacyclin receptor. Br J Pharmacol 1991;102:260-6.
22. Seiler SM, Brassard CL, Federici ME, et al. 2-[3-[2-(4,5-Diphenyl2-oxazolyl)ethyl]phenoxy]acetic acid (BMY 42393): a new structurally novel prostacyclin partial agonist: 1. Inhibition of platelet aggregation and mechanism of action. Thromb Res 1994;74: 115-23.
23. 2 receptor blocking drug on platelets and vascular airways smooth muscle. Br J Pharmacol 1989;97:783-94.
24. Kawai Y, Ohnashi T. Effects of isocarbacyclin, a stable prostacyclin analogue, on monkey isolated cerebral and peripheral arteries. Br J Pharmacol 1994;112:635-9.
25. Qian YM, Jones RL. Inhibition of rat colon contractility by prostacyclin (IP-) receptor agonists: involvement of NANC neurotransmission. Br J Pharmacol 1995;115:163-71.
26. Hamasaki Y, Saga T, Said SI. Autonomic innervation of pulmonary artery: evidence for non-adrenergic non-cholinergic relaxation. Am Rev Respir Dis 1983;127:300-5.
27. Kubota E, Hamasaki Y, Sata T, Saga T, Said SI. Autonomic innervation of pulmonary artery: evidence for nonadrenergic noncholinergic inhibitory system. Exp Lung Res 1988;14:349-58.
28. Maggi CA, Patacchini R, Perretti F, et al. Sensory nerves, vascular endothelium and neurogenic relaxation of the guinea pig isolated pulmonary artery. Naunyn Schmiedebergs Arch Pharmacol 1990; 342:78-84.
29. Hadházy P, Malomvolgyi B, Magyar K, Debreczeni LA, Hutás I. Species dependent relaxation of intrapulmonary arteries (IPA) of rabbits, dogs and humans by prostacyclin. Prostaglandins 1985;29:673-88.
30. 3 muscarinic receptors in human pulmonary arteries. Br J Pharmacol 1996;119: 149-57.
31. Hamilton TC, Weir SW, Weston AH. Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br J Pharmacol 1986;88:103-11.
32. Yamashita T, Masuda Y, Tanaka S. Inhibitory properties of NIP-121, a potassium channel opener, on high potassium and norepinephrine-induced contraction and calcium mobilisation in rat aorta. J Cardiovasc Pharmacol 1994;24:890-5.
33. Okabe K, Kajioka S, Nako K, Kitamura K, Kuriyama H, Weston AH. Actions of cromakalim on ionic currents recorded from single smooth muscle cells of the rat portal vein. J Pharmacol Exp Ther 1990;252:832-9.
34. McCormack DG, Mak JCW, Coupe MO, Barnes PJ. Calcitonin gene-related peptide vasodilation of human pulmonary vessels. J Appl Physiol 1989;67:1265-70.
35. Siegel G, Emden J, Wenzel K, Mironneau J, Stock G. Potassium channel activation in vascular smooth muscle. In: Frank GB, Bianchi P, Keurs HEDJ ten, et al., eds. Excitation-contraction coupling in skeletal, cardiac, and smooth muscle. Adv Exp Med Biol; New York: Plenum Press, 1992:53-72.
36. Jackson WF, Konig A, Dambacher T, Busse R. Prostacyclin-induced vasodilation in rabbit heart is mediated by ATP-sensitive potassium channels. Am J Physiol 1993;264:H238-43.
37. Negishi M, Hashimoto H, Yatsunami K, Kurozumi S, Ichikawa A. TEI-9063, a stable and highly specific prostacyclin analogue for the prostacyclin receptor in mastocytoma P-815 cells. Prostaglandins 1991;42:225-37.
38. Jones RL. Prostacyclin analogues potentiate contraction of the guinea pig vas deferens to electrical field stimulation. Br J Pharmacol 1993;108:C16.
39. Stephenson RP. A modification of receptor theory. Br J Pharmacol 1956;11:379-93.
40. 2) and its analogs. Prostaglandins 1987;33:845-54.
41. Nakagawa O, Tanaka I, Usui T, et al. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in cardiovascular system. Circulation 1994;90:1643-7.
42. Colquhoun D, Henderson R, Ritchie JM. The binding of labelled tetrodotoxin to non-myelinated nerve fibres. J Physiol 1972;227: 95-126.
43. 2-mimetic, the actions of which are slowly reversed by receptor blockade. Br J Pharmacol 1989;96:875-87.